arrow
S

Salvatore Tafuto

Fondazione Pascale
H指数:32
被引数:3,021

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study

卡博替尼和替莫唑胺在晚期进展性神经内分泌肿瘤患者中的应用:一项II期研究

2026-04-100
OAAI
ARTEMIS: a pilot study comparing AI-based and expert therapeutic decisions in simulated clinical cases of neuroendocrine neoplasms

ARTEMIS:一项比较基于AI和专家治疗决策在神经内分泌肿瘤模拟临床病例中的试点研究

2025-12-230
OAAI
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial☆

链脲佐菌素联合5-氟尿嘧啶后给予依维莫司或相反顺序用于晚期胰腺神经内分泌肿瘤患者(SEQTOR-GETNE III期研究):一项随机临床试验☆

2025-12-020
OAAI
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

神经内分泌肿瘤骨转移:一项关于自然史和管理的意大利全国性调查结果

2025-11-180
OAAI
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy

AIMN, ITANET, SIE 联合立场文件:关于肽受体放射性核素治疗期间神经内分泌肿瘤类癌综合征及其危象的识别、预防和管理的联合立场文件

2025-10-070
OA
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group

间质肿瘤的扩展分子分析:意大利肉瘤组共识论文

2025-09-230
PREAI
FAP-α in soft tissue and bone sarcomas: A new potential diagnostic and therapeutic biomarker in the era of precision medicine

软组织和骨肉瘤中的FAP-α:精准医学时代一种新的潜在诊断和治疗生物标志物

2025-07-140
OAAI
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma

SaLudo: lurbinectedin加阿霉素作为平滑肌肉瘤一线治疗的随机IIb/III期研究

2025-02-110
OAAI
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).
2024-10-122
OAAI
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
2024-09-010
PRE
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial
LANCET
IF88.5
2024-06-013
PRE
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours (vol 188, pg 39, 2023)
2024-05-010
OA
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group
2024-05-012
OAAI